Advanced Medical Solutions revenue rises as 2026 EBITDA guidance holds

The key points

Advanced Medical Solutions Group has delivered first-half revenue growth despite order timing, de-stocking and a demanding comparison with the prior year.

The tissue-healing medical device company expects revenue of approximately £115.2 million for the six months ended 30 June 2026, up from £110.8 million in the same period of 2025. That represents growth of roughly 4.0%.

Management also says the integration of Peters Surgical and Syntacoll remains on track. Most importantly for near-term expectations, the board remains confident that full-year 2026 EBITDA will be in line with current market expectations.

EBITDA means earnings before interest, tax, depreciation and amortisation. It is commonly used to assess the underlying operating performance of a business before financing costs and certain non-cash accounting charges.

Key measure	H1 2026 expectation	H1 2025	Change
Revenue	Approximately £115.2 million	£110.8 million	Approximately 4.0% higher
Full-year EBITDA	In line with current market expectations	Not disclosed	Guidance maintained
Peters Surgical and Syntacoll integration	On track	Not disclosed	Positive progress statement

Why the revenue performance needs some context

The headline revenue increase is encouraging, but this was not an entirely clean half for AMS.

Some orders that had been expected during the first half shipped later than planned in early July. This means they fell outside the reporting period, even though the delay appears to have been relatively short.

Timing effects matter because they can make one six-month period look weaker and the following period stronger without necessarily changing underlying customer demand. AMS has not disclosed the value of the delayed orders, so investors cannot quantify how much higher first-half revenue might otherwise have been.

The company also highlighted de-stocking connected with its strategy of expanding direct sales in Europe. De-stocking means reducing inventory held within a supply chain. In this case, it had a negative effect on sales during the period.

That is an important distinction. The sales impact is linked to a change in how AMS reaches customers rather than the company explicitly reporting weaker end-market demand. Even so, the announcement does not quantify the effect or state when this adjustment will be completed.

A difficult comparison with 2025

AMS was also measuring its performance against a strong first half in 2025.

The company said the previous period benefited from the phasing of orders from one key strategic partner in its Advance Closure division. Order phasing refers to when purchases fall within a reporting period. A large order arriving early can flatter one half and create a tougher comparison the following year.

Against that backdrop, delivering revenue growth of approximately 4.0% looks reasonably resilient. It suggests AMS was able to move forward despite several factors that held back the reported first-half number.

However, the update does not provide divisional revenue, organic growth, margins, cash flow or profit figures. That limits the conclusions investors can draw before the full half-year results are published.

Integration remains a central part of the story

The integration of Peters Surgical and Syntacoll remains on track, according to the board.

That is a useful reassurance because AMS has identified the Peters Surgical acquisition as a route to operational and commercial synergies, further international expansion and a greater proportion of sales through its own direct teams.

Direct sales can give a company greater control over customer relationships and commercial execution. They may also change ordering patterns as inventory moves away from distributors and into a new sales structure, which helps explain the de-stocking noted in this update.

Still, “on track” is a broad statement. AMS has not disclosed integration costs, synergy delivery, milestones or separate financial contributions from Peters Surgical and Syntacoll in this announcement. Investors will need the detailed interim results to judge progress more precisely.

The EBITDA outlook is the most important reassurance

The strongest part of the announcement is the maintained full-year EBITDA outlook.

Despite the delayed shipments, European de-stocking and demanding comparison, the board remains confident that 2026 EBITDA will meet current market expectations. The specific market expectation figure is not disclosed in the RNS, so the guidance cannot be translated into an exact profit number from this announcement alone.

Maintaining guidance suggests management does not currently see the first-half timing issues as sufficient to derail the full-year plan. The early-July shipment of delayed orders may also mean that part of the missed first-half revenue has simply moved into the second half.

However, the update does not disclose an expected split of revenue or earnings between the two halves. Investors should therefore avoid assuming that every first-half headwind will automatically reverse.

The EBITDA statement is formally treated as a profit forecast under Rule 28 of the Takeover Code. The directors confirmed that it was properly compiled and that the accounting basis was consistent with the group’s existing policies. They also said it should be read alongside the assumptions in the relevant Scheme Document.

Positives and risks for AMS investors

The positives

• First-half revenue is expected to rise to approximately £115.2 million.
• Growth was achieved despite delayed shipments and de-stocking.
• The comparison with H1 2025 was unusually demanding because of order phasing.
• The Peters Surgical and Syntacoll integrations remain on track.
• Full-year 2026 EBITDA guidance remains in line with current market expectations.

Points to watch

• The financial impact of orders delayed into July was not disclosed.
• The scale and expected duration of European de-stocking were not disclosed.
• There is no information on margins, cash generation or integration costs.
• Current market expectations for EBITDA were not quantified.
• The update provides no divisional performance breakdown.

What comes next

The next detailed results will need to show whether revenue growth is translating into healthy profitability and cash generation.

Investors should also look for evidence that the July shipments were completed as expected, that European de-stocking is progressing and that the integration programme is delivering measurable benefits.

For now, this is a steady update rather than a dramatic one. AMS has grown revenue through a complicated reporting period and retained confidence in its full-year EBITDA outcome. The missing detail means there is more work to do before the quality of that growth can be fully assessed, but the maintained outlook provides a constructive signal.